Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Merus N.V.

< Previous 1 2 Next >
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Business Update Conference Call
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Pricing of Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
CORRECTING and REPLACING --Merus Provides 2023 Outlook
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Provides 2023 Outlook
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.